{"id":50986,"date":"2022-11-17T13:02:16","date_gmt":"2022-11-17T12:02:16","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/research-published-in-melanoma-management-finds-that-99-of-patients-with-uveal-melanoma-tested-with-decisiondx-um-gain-value-from-the-results\/"},"modified":"2022-11-17T13:02:16","modified_gmt":"2022-11-17T12:02:16","slug":"research-published-in-melanoma-management-finds-that-99-of-patients-with-uveal-melanoma-tested-with-decisiondx-um-gain-value-from-the-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/research-published-in-melanoma-management-finds-that-99-of-patients-with-uveal-melanoma-tested-with-decisiondx-um-gain-value-from-the-results\/","title":{"rendered":"Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx\u00ae-UM Gain Value from the Results"},"content":{"rendered":"
\n

\nThere was no significant difference in decision regret levels among those receiving a low- (Class 1A), intermediate- (Class 1B) or high-risk (Class 2) DecisionDx-UM test result<\/i>\n<\/p>\n

FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL<\/a> #CSTL<\/a>–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study completed in collaboration with the Melanoma Research Foundation (MRF) in which most patients diagnosed with uveal melanoma (UM) indicated their desire for prognostic testing at diagnosis, reported finding value in their test result and experienced lower decision regret, regardless of whether their test result indicated that their UM tumor was at a high or low risk of metastasis. The study, titled \u201cUveal melanoma patient attitudes towards prognostic testing using gene expression profiling,\u201d was published in Melanoma Management<\/i> and can be viewed on Castle’s website<\/a>.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe were excited to embark on this collaboration with Castle Biosciences, a leader in prognostic testing for uveal melanoma, as few studies have explored patients\u2019 perspectives towards prognostic testing and the value patients can gain by having personalized prognostic information,\u201d said Kyleigh LiPira, M.B.A., chief executive officer of the MRF. \u201cThe more information patients can have in advance of making treatment decisions is critical to having successful outcomes. This data further reinforces the need for patients to understand their options so they can be active participants in their care.\u201d\n<\/p>\n

\nThe study aimed to assess patient experiences with DecisionDx\u00ae-UM testing and other prognostic methods through an online questionnaire that was distributed by the MRF\u2019s CURE OM initiative. CURE OM (the Community United for Research and Education of Ocular Melanoma) is the MRF\u2019s initiative to increase awareness, education and research funding for ocular melanoma, while improving the lives of people affected by this disease. The questionnaire captured anonymized information regarding patients\u2019 experiences with prognostic testing following a diagnosis of UM; 177 patients completed the survey.\n<\/p>\n

\nHighlights from the study include the following:\n<\/p>\n